Primary hypercholesterolaemia (heterozygous familial & non-familial) or mixed dyslipidaemia in adults & paed ≥10 yr w/ heterozygous familial hypercholesterolaemia as adjunct to diet in combination w/ a statin or statin w/ other lipid-lowering therapies in patients unable to reach LDL-C goals w/ max tolerated dose of statin, or as monotherapy or in combination w/ other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. In combination w/ other lipid-lowering therapies for adults & paed ≥10 yr w/ homozygous familial hypercholesterolaemia. Adults w/ established atherosclerotic CV disease (MI, stroke or peripheral arterial disease) to reduce CV risk by lowering LDL-C levels, as an adjunct to correction of other risk factors in combination w/ the max tolerated dose of a statin w/ or w/o other lipid-lowering therapies, or as monotherapy or in combination w/ other lipid-lowering therapies in those who are statin-intolerant, or for whom a statin is contraindicated.
SC Administer into the abdomen, thigh or upper arm region.Adult & paed ≥10 yr Primary hypercholesterolaemia & mixed dyslipidaemia 140 mg every 2 wk or 420 mg once mthly. Homozygous familial hypercholesterolaemia Initially 420 mg once mthly. Can be up-titrated to 420 mg once every 2 wk after 12 wk of treatment if response is not achieved. Patients on apheresis Initially 420 mg every 2 wk to correspond w/ apheresis schedule. AdultEstablished atherosclerotic CV disease 140 mg every 2 wk or 420 mg once mthly.
Not to be administered IV or IM. Closely monitor patients w/ moderate hepatic impairment. Severe hepatic impairment (Child-Pugh C). Not to be used during pregnancy & lactation.
Sign Out
